An international meeting on scalp disorders was recently held in Rome. Psoriasis, seborrheic dermatitis, sebopsoriasis and primary cicatricial alopecias were the main topics. In this circumstance the results of the clinical trials in scalp psoriasis with a new fixed combination containing calcipotriene 50 μg/g and betamethasone (0.5 mg/g) as dipropionate in lipophilic gel (Xamiol®) were shown. Calcipotriene plus betamethasone dipropionate gel is a fast-acting, very efficacious, safe, oncedaily treatment for scalp psoriasis ranging from mild to very severe. It is more efficacious than calcipotriene, betamethasone dipropionate and the gel vehicle. The safety profile is similar to that of betamethasone dipropionate and better than calcipotriol. Two 52-week studies have shown that calcipotriene plus betamethasone dipropionate gel can be safely used longterm.
Scalp disorders
Piaserico S.;
2010
Abstract
An international meeting on scalp disorders was recently held in Rome. Psoriasis, seborrheic dermatitis, sebopsoriasis and primary cicatricial alopecias were the main topics. In this circumstance the results of the clinical trials in scalp psoriasis with a new fixed combination containing calcipotriene 50 μg/g and betamethasone (0.5 mg/g) as dipropionate in lipophilic gel (Xamiol®) were shown. Calcipotriene plus betamethasone dipropionate gel is a fast-acting, very efficacious, safe, oncedaily treatment for scalp psoriasis ranging from mild to very severe. It is more efficacious than calcipotriene, betamethasone dipropionate and the gel vehicle. The safety profile is similar to that of betamethasone dipropionate and better than calcipotriol. Two 52-week studies have shown that calcipotriene plus betamethasone dipropionate gel can be safely used longterm.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
